Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · IEX Real-Time Price · USD
2.850
-0.050 (-1.72%)
At close: May 17, 2024, 4:00 PM
2.900
+0.050 (1.75%)
After-hours: May 17, 2024, 7:29 PM EDT
Akoya Biosciences Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Akoya Biosciences stock have an average target of 7.79, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 173.33% from the current stock price of 2.85.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AKYA stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 3 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $10 → $6 | Strong Buy | Maintains | $10 → $6 | +110.53% | May 14, 2024 |
| BTIG | BTIG | Strong Buy Maintains $9 → $6 | Strong Buy | Maintains | $9 → $6 | +110.53% | May 14, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $12 → $10 | Buy | Maintains | $12 → $10 | +250.88% | Mar 6, 2024 |
| UBS | UBS | Strong Buy Maintains $7 → $7.5 | Strong Buy | Maintains | $7 → $7.5 | +163.16% | Mar 5, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +250.88% | Mar 5, 2024 |
Financial Forecast
Revenue This Year
118.08M
from 96.63M
Increased by 22.19%
Revenue Next Year
139.83M
from 118.08M
Increased by 18.42%
EPS This Year
-0.86
from -1.43
EPS Next Year
-0.53
from -0.86
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 122.5M | 147.4M | 187.9M | 200.7M | 232.2M |
| Avg | 118.1M | 139.8M | 165.9M | 175.9M | 194.9M |
| Low | 112.7M | 131.9M | 141.7M | 150.6M | 157.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 26.8% | 24.8% | 34.4% | 20.9% | 32.0% |
| Avg | 22.2% | 18.4% | 18.7% | 6.0% | 10.8% |
| Low | 16.6% | 11.7% | 1.3% | -9.2% | -10.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.76 | -0.51 | -0.13 | -0.01 | 0.23 |
| Avg | -0.86 | -0.53 | -0.23 | -0.13 | 0.02 |
| Low | -0.88 | -0.59 | -0.31 | -0.24 | -0.18 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.